Chapter 3

Ownership and Control

Vital Farms' cap table is unusual for a founder-led consumer company. Founder Matthew O'Hayer has cut his stake from 27.4% at the IPO to 16.3% and, in February 2026, left the board entirely; current officers and directors together own under 4%, and two index funds hold roughly 19% [1]. Governance hygiene is largely sound, but three features bear on the reinvestment cycle: a combined chair and CEO, a construction contract with the CEO's father, and a public-benefit charter that legally subordinates share-price maximization.

The owner's table

As of April 2026, Vital Farms had 42.8 million shares outstanding, and the register concentrates in a small set of names [2]. The founder remains the single largest holder at 16.3%. The two big passive managers, BlackRock and Vanguard, together hold about 19%. Everyone actually running the company — all 15 executive officers and directors as a group — owns 3.9%, and the chair-and-CEO himself owns 1.9%.

Source: 2026 Proxy Statement, Security Ownership table (42,848,454 shares outstanding as of April 23, 2026) [3].

Source: 2026 Proxy Statement, Security Ownership of Certain Beneficial Owners and Management [4].

The register has no dual-class structure and no super-voting shares: economic ownership and voting power are the same thing. That matters for a minority holder — control here follows the cash-on-the-table register, not a founder's protected vote. It also means the passive index funds, not any insider, are now the swing block on any shareholder vote.

The founder steps back

O'Hayer's ownership has fallen in a steady line, not a cliff. Successive Schedule 13G filings show the stake moving from 27.4% (February 2021) through 23.4% (February 2024) to 16.1% (November 2025), before the proxy recorded 16.3% in April 2026 [5]. That is roughly 11 percentage points of the company distributed over five years — a deliberate, disclosed wind-down rather than a single exit.

Source: SEC Schedule 13G / 13G-A filings, 2021–2026; latest point confirmed in the 2026 Proxy Statement [6].

The step change is at the board, not in the stake. O'Hayer resigned as Executive Chairperson and left the board in February 2026, and in March 2026 signed a resignation agreement under which he serves only as a non-employee advisor, drawing no compensation in fiscal 2025 [7]. The founder who built the farmer network is now a large but passive shareholder — one who has been a consistent seller — with no formal control of the company he founded.

Control concentrates as the founder leaves

O'Hayer's departure did not disperse authority; it consolidated it. Russell Diez-Canseco now holds all three top roles — President, Chief Executive Officer, and Executive Chairperson — and is the only one of the eight directors the board does not classify as independent [8]. The remaining seven directors are independent, and Denny Marie Post serves as Lead Independent Director, the structural counterweight to a combined chair and CEO [9].

The surrounding hygiene is better than the concentrated top job might suggest. The board runs a clawback policy on incentive pay, prohibits hedging and all but tightly-controlled pledging of shares, and raised its stock-ownership guidelines in 2025 to five times base salary for the CEO — with every officer and director reported in compliance [10]. Management pay is modest for the size of the business: the CEO's fiscal-2025 total compensation was $3.6 million, of which roughly $2.1 million was equity, for a CEO-to-median-employee pay ratio of 44:1 [11] [12].

Two features cut the other way. The board is classified into three staggered classes, each serving a three-year term, so only part of the board stands for election in any year — an entrenchment feature that slows any outside push for change, and one the board has explicitly chosen to keep [13]. And the concentration of chair and CEO arrives precisely as the company enters its most capital-intensive stretch — the multi-year plant build that governs whether the free-cash-flow question resolves (Cash Conversion). Independent oversight of that spend now rests on a lead director and committee structure rather than a separate chair.

The related-party build

The sharpest company-specific flag sits inside the capital program itself. Vital Farms uses Sandpebble Builders Preconstruction for project-management services on its egg-processing facilities, including Vital Crossroads, the second washing-and-packing plant in Seymour, Indiana. Victor Canseco, Sandpebble's owner and principal, is the father of CEO Russell Diez-Canseco, and the company paid Sandpebble approximately $2.46 million in fiscal 2025 [14].

The amount is small against the roughly $82 million of fiscal-2025 capex, and the payment is disclosed and routed through the audit committee's related-person-transaction policy, which requires arm's-length review of any deal above $120,000 [15]. What makes it worth a professional investor's attention is not the size but the location: the CEO's family is a paid vendor on the very growth-capex build that the investment case turns on, and that vendor relationship persists into the larger Vital Crossroads spend still ahead. The read here is a watch item, not an indictment — the disclosure is clean and the sum immaterial — but a related-party vendor embedded in the swing capital project is the kind of arrangement whose scale is worth tracking as Vital Crossroads ramps.

Sellers on the way up, buyers at the bottom

Insider trading over the last twelve months splits cleanly by direction and by timing. On the way up, the selling was concentrated in the two most senior insiders: O'Hayer disposed of 95,000 shares for about $2.7 million and Diez-Canseco sold 16,734 shares for about $0.6 million, both through pre-set 10b5-1 plans.

The buying tells the more interesting story. After the stock's roughly 75% drawdown and the May 2026 guidance cut, a broad group of directors and officers bought on the open market — thirteen purchases totaling about $0.6 million, with eleven of them clustered in a single week of mid-May at prices near $8 to $10.

Source: SEC Form 4 filings, open-market purchases March–May 2026 (aggregated); larger 10b5-1 sales by O'Hayer and Diez-Canseco over the same window are drawn from the same filings.

The buying is a genuine signal, but it deserves a fair caveat. Directors and officers face a five-year runway to meet the raised ownership guidelines, so some of these purchases help satisfy that requirement rather than express pure conviction [16]. Even so, the concentration of eleven insiders buying in one week, at multi-year lows, after the worst guidance cut in the company's public life, is the first cluster of open-market insider buying in the record — a datapoint that cuts against the bear case on management's own read of value.

The public-benefit lens

One structural feature of Vital Farms is not a discretionary governance choice but a charter obligation. As a Delaware public benefit corporation and Certified B Corp, the board has a legal duty to balance three things: the pecuniary interest of stockholders, the interests of those materially affected by the company's conduct, and the specific public benefits named in its certificate of incorporation [17].

The company's own filings state the consequence plainly: in balancing these interests, the board "may take actions that do not maximize stockholder value" [18]. The structure also creates a litigation channel that ordinary corporations lack: holders of as little as 2% of shares (or $2 million of stock) can bring a derivative claim alleging the board failed to balance those interests [19]. For most of the company's history this has been an abstraction, aligned with the brand that commands the price premium. It becomes a live question only if the stakeholder mission and shareholder returns ever pull hard in opposite directions — a tension a minority holder accepts as a condition of owning the shares.

Where this leaves the reader

The ownership picture is a balance of alignment and concern, not a verdict either way. On the alignment side: no dual-class control, an independent board majority with a lead independent director, disciplined pay, hedging and pledging restrictions, and a cluster of insider buying at the lows. On the concern side: a founder who has sold steadily and left, a chair-and-CEO role concentrated in one person just as the capital cycle peaks, a classified board that resists outside pressure, a related-party vendor inside the growth-capex program, and a charter that legally permits the board to weigh other interests above the share price. None of these is disqualifying on its own; together they describe a company where a minority investor is trusting an independent board and a lead director — rather than a large aligned insider block — to steward the reinvestment that the thesis depends on.